Helen Heslop, MD

Adjunct Professor of Medicine, Institute for Academic Medicine
Full Affiliate Member, Research Institute
Houston Methodist


Dr. Heslop's initial faculty appointment was as Assistant Member of the Division of Bone Marrow Transplantation in the Department of Hematology-Oncology at the St. Jude Children's Research Hospital, in Memphis in 1991. She was promoted to Associate Member in 1994. She also held an appointment as Associate Professor in the Department of Pediatrics at the University of Tennessee in Memphis. Dr. Heslop received her current appointments at the Baylor College of Medicine in Houston, Texas in 1997. She was named as the first Dan L. Duncan Chair for Baylor College of Medicine in 2006.

Description of Research

Dr. Heslop's research centers on adoptive immunotherapy with gene-modified effector cells to improve hemopoietic stem cell transplantation and cancer therapy. She currently directs a Lymphoma SPORE program and a program project grant from the NCI, as well as a Specialized Center of Research from the Leukemia and Lymphoma Society. Her research focus is to develop safe and effective T-cell immunotherapies for lymphoma and other Epstein-Barr virus-associated malignancies, including Hodgkin's Disease and nasopharyngeal cancer. Dr. Heslop also runs studies using third party CTLs to treat viral infections after transplant.

Areas Of Expertise

Cancer Adoptive immunotherapy Effector cells Hemopoietic stem cell transplantation

Clinical responses with T lymphocytes targeting malignancy-associated ? light chains
Ramos, CA, Savoldo, B, Torrano, V, Ballard, B, Zhang, H, Dakhova, O, Liu, E, Carrum, G, Kamble, RT, Gee, AP, Mei, Z, Wu, MF, Liu, H, Grilley, B, Rooney, CM, Brenner, MK, Heslop, H & Dotti, G 2016, Journal of Clinical Investigation, vol 126, no. 7, pp. 2588-2596. DOI:

T cells for viral infections after allogeneic hematopoietic stem cell transplant
Bollard, CM & Heslop, HE 2016, Blood, vol 127, no. 26, pp. 3331-3340. DOI:

Setting global standards for stem cell research and clinical translation: The 2016 ISSCR guidelines
Daley, GQ, Hyun, I, Apperley, JF, Barker, RA, Benvenisty, N, Bredenoord, AL, Breuer, CK, Caulfield, T, Cedars, MI, Frey-Vasconcells, J, Heslop, HE, Jin, Y, Lee, RT, McCabe, C, Munsie, M, Murry, CE, Piantadosi, S, Rao, M, Rooke, HM, Sipp, D, Studer, L, Sugarman, J, Takahashi, M, Zimmerman, M & Kimmelman, J 2016, Stem Cell Reports, vol 6, no. 6, pp. 787-797. DOI:

New ISSCR guidelines: Clinical translation of stem cell research
Kimmelman, J, Heslop, HE, Sugarman, J, Studer, L, Benvenisty, N, Caulfield, T, Hyun, I, Murry, CE, Sipp, D & Daley, GQ 2016, The Lancet, vol 387, no. 10032, pp. 1979-1981. DOI:

Policy: Global standards for stem-cell research
Kimmelman, J, Hyun, I, Benvenisty, N, Caulfield, T, Heslop, HE, Murry, CE, Sipp, D, Studer, L, Sugarman, J & Daley, GQ 2016, Nature, vol 533, pp. 311-313. DOI:

CAR-T cell therapy for lymphoma
Ramos, CA, Heslop, HE & Brenner, MK 2016, Annual Review of Medicine, vol 67, pp. 165-183. DOI:

Erratum: CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo (Science Translational Medicine (2016) 8:321 (321er1))
Hanley, PJ, Melenhorst, JJ, Nikiforow, S, Scheinberg, P, Blaney, JW, Demmler-Harrison, G, Cruz, CR, Lam, S, Krance, RA, Leung, KS, Martinez, CA, Liu, H, Douek, DC, Heslop, HE, Rooney, CM, Shpall, EJ, Barrett, AJ, Rodgers, JR & Bollard, CM 2016, Science Translational Medicine, vol 8, no. 321, 321er1. DOI:

Adoptive T-cell Therapy for Viral Disease in the Setting of Hematopoietic Cell Transplantation
Bollard, CM & Heslop, HE 2016, . in Thomas Hematopoietic Cell Transplantation: Fifth Edition. vol. 2-2, Wiley Blackwell, pp. 816-827. DOI:

Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch
Chang, EC, Liu, H, West, JA, Zhou, X, Dakhova, O, Wheeler, DA, Heslop, HE, Brenner, MK & Dotti, G 2015, Molecular Therapy. DOI:

Antigen-specific T cell therapies for cancer
Manzo, T, Heslop, HE & Rooney, CM 2015, Human Molecular Genetics, vol 24, no. R1, ddv270, pp. R67-R73. DOI:

Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes
Naik, S, Nicholas, SK, Martinez, CA, Leen, AM, Hanley, PJ, Gottschalk, SM, Rooney, CM, Hanson, IC, Krance, RA, Shpall, EJ, Cruz, CR, Amrolia, P, Lucchini, G, Bunin, N, Heimall, J, Klein, OR, Gennery, AR, Slatter, MA, Vickers, MA, Orange, JS, Heslop, HE, Bollard, CM & Keller, MD 2015, Journal of Allergy and Clinical Immunology. DOI:

Engineering haploidentical transplants
Naik, S & Heslop, HE 2015, Bone Marrow Transplantation, vol 50, no. 7, pp. 884-885. DOI:

Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies
Naik, S, Martinez, C, Leung, K, Sasa, G, Nguyen, NY, Wu, MF, Gottschalk, S, Brenner, M, Heslop, H & Krance, R 2015, Biology of Blood and Marrow Transplantation, vol 21, no. 7, pp. 1266-1272. DOI:

Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation
Zhou, X, Dotti, G, Krance, RA, Martinez, CA, Naik, S, Kamble, RT, Durett, AG, Dakhova, O, Savoldo, B, Stasi, AD, Spencer, DM, Lin, YF, Liu, H, Grilley, BJ, Gee, AP, Rooney, CM, Heslop, HE & Brenner, MK 2015, Blood, vol 125, no. 26, pp. 4103-4113. DOI:

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
Ninomiya, S, Narala, N, Huye, L, Yagyu, S, Savoldo, B, Dotti, G, Heslop, HE, Brenner, MK, Rooney, CM & Ramos, CA 2015, Blood, vol 125, no. 25, pp. 3905-3916. DOI:

Human epidermal growth factor receptor 2 (HER2) - Specific chimeric antigen receptor - Modified T cells for the immunotherapy of HER2-positive sarcoma
Ahmed, N, Brawley, VS, Hegde, M, Robertson, C, Ghazi, A, Gerken, C, Liu, E, Dakhova, O, Ashoori, A, Corder, A, Gray, T, Wu, MF, Liu, H, Hicks, J, Rainusso, N, Dotti, G, Mei, Z, Grilley, B, Gee, A, Rooney, CM, Brenner, MK, Heslop, HE, Wels, WS, Wang, LL, Anderson, P & Gottschalk, S 2015, Journal of Clinical Oncology, vol 33, no. 15, pp. 1688-1696. DOI:

Late-Onset Severe Chronic Active EBV in a Patient for Five Years with Mutations in STXBP2 (MUNC18-2) and PRF1 (Perforin 1)
Cohen, JI, Niemela, JE, Stoddard, JL, Pittaluga, S, Heslop, H, Jaffe, ES & Dowdell, K 2015, Journal of Clinical Immunology, vol 35, no. 5, pp. 445-448. DOI:

CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo
Hanley, PJ, Melenhorst, JJ, Nikiforow, S, Scheinberg, P, Blaney, JW, Demmler-Harrison, G, Cruz, CR, Lam, S, Krance, RA, Leung, KS, Martinez, CA, Liu, H, Douek, DC, Heslop, HE, Rooney, CM, Shpall, EJ, Barrett, AJ & Bollard, CM 2015, Science Translational Medicine, vol 7, no. 285, 285ra63. DOI:

Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells
Melenhorst, JJ, Castillo, P, Hanley, PJ, Keller, MD, Krance, RA, Margolin, J, Leen, AM, Heslop, HE, Barrett, AJ, Rooney, CM & Bollard, CM 2015, Molecular Therapy, vol 23, no. 1, pp. 179-183. DOI:

Survivin-specific T cell receptor targets tumor but not T cells
Arber, C, Feng, X, Abhyankar, H, Romero, E, Wu, MF, Heslop, HE, Barth, P, Dotti, G & Savoldo, B 2015, Journal of Clinical Investigation, vol 125, no. 1, pp. 157-168. DOI: